PCN115 COST UTILITY ANALYSIS OF 90Y-IBRITUMOMAB TIUXETAN FOLLOWING FIRST-LINE CHEMOTHERAPY COMPARED TO NO FOLLOW-UP IN PATIENTS WITH STAGE III OR IV FOLLICULAR LYMPHOMA IN SPAIN
Oct 1, 2009, 00:00
10.1016/S1098-3015(10)74366-7
https://www.valueinhealthjournal.com/article/S1098-3015(10)74366-7/fulltext
Title :
PCN115 COST UTILITY ANALYSIS OF 90Y-IBRITUMOMAB TIUXETAN FOLLOWING FIRST-LINE CHEMOTHERAPY COMPARED TO NO FOLLOW-UP IN PATIENTS WITH STAGE III OR IV FOLLICULAR LYMPHOMA IN SPAIN
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)74366-7&doi=10.1016/S1098-3015(10)74366-7
First page :
Section Title :
Open access? :
No
Section Order :
295